ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

trifluridine tipiracil drug combination

Also written as “TAS-102”, “Trifluridine/Tipiracil” and “Trifluridine and Tipiracil Tablets”.

Its studies are mostly in Colorectal Neoplasms · Breast Neoplasms · Liver Neoplasms · Kidney Diseases · Small Cell Lung Carcinoma, led by 11 companies.

Furthest: phase 3, since May 24, 201225 company-led studies, 7 open or runningNext primary completion: Aug 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only130 open or runningphase 3since May 24, 2012May 24, 2012none ahead
Sino Biopharmaceuticalits history only32 open or runningphase 3since Mar 6, 2026May 31, 2019Aug 2027phase 3 · NCT07483684
AbbVieits history only11 open or runningphase 3since Apr 7, 2026Apr 7, 2026May 2029phase 3 · NCT07525206
Criteriumits history only11 open or runningphase 2since Apr 30, 2025Apr 30, 2025Dec 31, 2027phase 2 · NCT06992258
Elevar Therapeuticsits history only10 open or runningphase 1since Aug 26, 2019Aug 26, 2019none ahead
GamaMabs Pharmaits history only10 open or runningphase 2since Jan 8, 2019Jan 8, 2019none ahead
Gilead Sciencesits history only11 open or runningphase 2since Apr 7, 2026Apr 7, 2026Dec 2028phase 2 · NCT07527858
Jiangsu HengRui Medicineits history only11 open or runningphase 3since Dec 26, 2023Dec 26, 2023none ahead
Lunan Pharmaceutical Groupits history only10 open or runningno phasesince Mar 19, 2026Mar 19, 2026none ahead
STCube11 open or runningphase 1since May 27, 2026May 27, 2026Jul 31, 2028phase 1 · NCT07656038

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of STCube only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 27, 2026First study: phase 1 study in Colonrectal Cancer (CRC)First studyNCT07656038 · 45 planned

Ahead

  1. Jul 31, 2028Primary completion: phase 1 study in Colonrectal Cancer (CRC)NCT07656038

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study STCube leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656038Colonrectal Cancer (CRC)1Not yet recruitingJul 31, 202845

How it is read

Names in the registry

  • “TAS-102”, 11 entries
  • “Trifluridine/Tipiracil”, 3 entries
  • “Trifluridine and Tipiracil Tablets”, 2 entries
  • “Trifluridine-Tipiracil”, 1 entry
  • “Fruquintinib+ Lonsurf (trifluridine and tipiracil)”, 1 entry

Codes read as this program: TAS102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.